Literature DB >> 2641987

Increases in plasma concentrations of a prostaglandin metabolite in acute airway obstruction.

D P Skoner1, P Fireman, H W Davis, R Wall, L A Caliguiri.   

Abstract

Plasma concentrations of a stable prostaglandin F2 alpha metabolite were measured by radioimmunoassay during and after recovery from acute airway obstruction in 15 infants. Mean (SEM) metabolite concentrations (ng/l) in plasma obtained both before (1033 (418)) and after (1470 (413)) initial treatment for airway obstruction were significantly higher than those obtained from the same subjects after resolution of the obstruction--25.5 (6.6)--and those obtained from two comparison groups. Infants positive for respiratory syncytial virus (mean 1122 (227)) had significantly higher concentrations than those who were negative (207.6 (46)). Additionally, seven subjects with a history of recurrent wheezing after resolution of airway obstruction had a significantly higher mean level (3500 (1400)) during attacks of airway obstruction than those without (600 (100)). These data suggest that prostaglandin F2 alpha mediates respiratory inflammation in airway obstruction and that trials of specific anti-inflammatory agents for the treatment of airway obstruction may be warranted.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2641987      PMCID: PMC1792543          DOI: 10.1136/adc.64.8.1112

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  19 in total

1.  Clinically useful method for the isolation of respiratory syncytial virus.

Authors:  C B Hall; R G Douglas
Journal:  J Infect Dis       Date:  1975-01       Impact factor: 5.226

2.  Endogenous levels of 15-keto-dihydro-prostaglandins in human plasma. Parameters for monitoring prostaglandin synthesis.

Authors:  B Samuelsson; K Gréen
Journal:  Biochem Med       Date:  1974-11

3.  The relationship between proved viral bronchiolitis and subsequent wheezing.

Authors:  J C Rooney; H E Williams
Journal:  J Pediatr       Date:  1971-11       Impact factor: 4.406

4.  Virus and interferon effects on cellular prostaglandin biosynthesis.

Authors:  F A Fitzpatrick; D A Stringfellow
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

5.  Increased plasma levels of 15-keto-13,14-dihydro-prostaglandin F2X after allergen-provoked asthma in man.

Authors:  K Gréen; P Hedqvist; N Svanborg
Journal:  Lancet       Date:  1974-12-14       Impact factor: 79.321

6.  Prostaglandins: their disappearance from and release into the circulation.

Authors:  S H Ferreira; J R Vane
Journal:  Nature       Date:  1967-12-02       Impact factor: 49.962

7.  The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection.

Authors:  R C Welliver; D T Wong; M Sun; E Middleton; R S Vaughan; P L Ogra
Journal:  N Engl J Med       Date:  1981-10-08       Impact factor: 91.245

8.  The etiologic and epidemiologic spectrum of bronchiolitis in pediatric practice.

Authors:  F W Henderson; W A Clyde; A M Collier; F W Denny; R J Senior; C I Sheaffer; W G Conley; R M Christian
Journal:  J Pediatr       Date:  1979-08       Impact factor: 4.406

9.  Effects of arachidonic acid, monohydroxyeicosatetraenoic acid and prostaglandins on the release of mucous glycoproteins from human airways in vitro.

Authors:  Z Marom; J H Shelhamer; M Kaliner
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

Review 10.  Bronchiolitis and asthma: possible common pathogenetic pathways.

Authors:  K McIntosh
Journal:  J Allergy Clin Immunol       Date:  1976-06       Impact factor: 10.793

View more
  2 in total

Review 1.  The respiratory syncitial virus and its role in acute bronchiolitis.

Authors:  M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

2.  Increases in plasma concentrations of a prostaglandin metabolite in acute airway obstruction.

Authors:  I Amirav
Journal:  Arch Dis Child       Date:  1990-05       Impact factor: 3.791

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.